Socialiya - Entertainment. Knowledge. Community.
Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli Lilly's up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public tes...

BUSINESS NEWS June 13, 2026

Lilly unveils first clinical data behind $2.3B Ajax deal, showing JAK inhibitor works ‘right out of the gate’

Eli Lilly's up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma...

2 views 0 likes 0 comments
Share:
Eli Lilly's up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma...

Author: Fierce Biotech

Read Original Article

Related News

Advertisement
socialiya
Advertisement

Top Categories

Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya
Advertisement
socialiya